Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver

Ankara University202 enrolled

Overview

Radioembolization is an established treatment option for patients with unresectable primary and secondary liver tumors. Microspheres containing 90Y are injected intraarterially to deliver a high radiation dose to the tumors. Despite of our knowledge on the effectiveness of 90Y glass microspheres in the treatment of HCC, literature data on the treatment of metastatic colorectal cancer (mCRC) patients with 90Y glass microspheres is limited. In the recent EANM guideline variable healthy liver doses are recommended for patients with mCRC with an effective tumor dose recommendation based on a study with limited number of patients. Primary objectives; Investigate effective tumor dose and safe healthy liver dose in radioembolization for colorectal cancer liver metastasis using multicompartment dosimetry Secondary objectives; Investigate dose-response and dose-toxicity relationships, time to progress, concordance between pretreatment and posttreatment dose calculations.

Study Type

OBSERVATIONAL

Enrollment

202

Conditions

Transarterial Radioembolization

Interventions

TherasphereDEVICE

Transarterial radioembolization

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * over 18 years old * histopathologically proven colorectal cancer diagnosis * treated with radioembolization for liver metastases with Y90 glass microspheres in lobar or segmental fashion * have follow-up data at least 6 months after radioembolization Exclusion Criteria: * no PET-CT, CT or MR of the liver within last 6 weeks prior to radioembolization. No PET-CT, CT or MR of the liver 2-4 months after radioembolization Poor image quality Previous local treatment or surgery for the liver

Locations (8)

Cukurova University Medical School

Adana, Turkey (Türkiye)

Ankara University Medical School

Ankara, Turkey (Türkiye)

Hacettepe Univeristy Medical School

Ankara, Turkey (Türkiye)

Istanbul University Capa Medical School

Istanbul, Turkey (Türkiye)

Istanbul University Cerrahpasa Medical School

Istanbul, Turkey (Türkiye)

Marmara University Medical School

Istanbul, Turkey (Türkiye)

Yeditepe University Medical School

Istanbul, Turkey (Türkiye)

Dokuz Eylul University Medical School

Izmir, Turkey (Türkiye)

Outcomes

Primary Outcomes

effective tumor dose and safe healthy liver dose

Compare the mean effective tumor doses effective tumour dose (in Gy) of patients with or without response to radioembolization for colorectal cancer liver metastasis.

Time frame: 3th month after treatment

Secondary Outcomes

dose (in Gy) -response and dose (in Gy)-toxicity relationships

Investigate dose-response and dose-toxicity relationships after transarterial radioembolization.

Time frame: 6th month after treatment